Cryptogenic cirrhosis: A vanishing entity

Journal of Association of Physicians of India

Volumn 57, Issue 11, 2009, Pages

  Desai, H G ^a  

^a JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HEPATITIS B SURFACE ANTIGEN;

ARTICLE; AUTOIMMUNE HEPATITIS; BIOPSY; BLOOD; BREATH ANALYSIS; CLASSIFICATION; ELASTOGRAPHY; FATTY LIVER; HEPATITIS VIRUS; HUMAN; ISOLATION AND PURIFICATION; LIVER CIRRHOSIS; LIVER FUNCTION TEST; PATHOLOGY; RISK FACTOR; VIRUS HEPATITIS;

BIOLOGICAL MARKERS; BIOPSY; BREATH TESTS; ELASTICITY IMAGING TECHNIQUES; FATTY LIVER; HEPATITIS B SURFACE ANTIGENS; HEPATITIS VIRUSES; HEPATITIS, AUTOIMMUNE; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; RISK FACTORS;

EID: 70350632913     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Anthony PP, Ishah KG, Nayak NC, Pouslen ME, Scheuer PJ, Sorbin LH. The morphology of cirrhosis: definition, nomenclature, and classification. Bulletin of the World Health Organization 1977; 55: 521-40.
2. Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J Clin Pathol 1978;31:395-414.
3. Kasliwal RM, Sharma BM, Chaturvedi GC. Aetiological factors of cirrhosis of the liver in adults in India. A study of 290 cases. J Indian Med Assoc 1965; 44: 407-13.
4. Blumberg BS, Alter HJ, Visnich S. A "new" antigen in leukemia sera. JAMA 1965; 191: 541-6.
5. Kaneko S, Miller RH, Di Bisceglie AM, Feinstone SM, Hoofnagle JH, Purcell RH. Detection of hepatitis B virus DNA in serum by polymerase chain reaction. Application for clinical diagnosis. Gastroenterology 1990; 99: 799-804.
6. Alhababi F, Sallam TA, Tong CY. The significance of 'anti-HBc only' in the clinical virology laboratory. J Clin Virol 2003;27:162-9.
7. Rizzetto M, Canese MG, Arico S, et al. Immunofluorescence detection of a new antigen-antibody system (delta/antidelta) associated with hepatitis B virus in liver and in serum of HBsAg carriers. Gut 1977; 18: 997-1003.
8. Desai HG. Prevention and control of hepatitis B virus in India. Natl Med J India 1988; 1: 233-6.
9. Desai HG, WHO recommendation for hepatitis B immunization. Indian J Gastroenterol 1986; 5: 291.
10. Centres for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. MMWR 2006; 55: 1-41.
11. Choo Q-L, Kuo G, Weiner AJ, Dverby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
12. Abdel-Wahab MF, Zakaria S, Kamel M, et al. High seroprevalence of hepatitis C infection among risk groups in Egypt. Am J Trop Med Hyg 1994;51:563-7.
13. Johnson PJ, McFarlane IG. Meeting repor t: International Autoimmune Hepatitis Group. Hepatology 1993;18:998-1005.
14. Alvarez F, Berg PA, Bianchi FB. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
15. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease, Mayo Clin Proc 1980; 55: 434-8.
16. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology (Baltimore) 1990; 12: 1106-10.
17. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43(Suppl 1):S99-S112.
18. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study. Hepatology 2000;32:689-92.
19. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
20. Baldridge AD, Perez-Atayde AR, Graeme-Cook F, Higgins L, Lavine JE. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr 1995;127:700-4
21. Amarapurkar D, Das HS. Chronic liver disease in diabetes mellitus. Trop Gastroenterol 2002; 23: 3-5.
22. Mehta NM, Desai HG. Persistent transaminase elevation due to heterozygous (familial) apolipoprotein B deficiency. Indian J Gastroenterol 1997; 16: 158-9.
23. Gupte P, Dudhade A, Desai HG. Acquired apolipoprotein B deficiency with chronic hepatitis C virus infection. Indian J Gastroenterol 2006; 25: 311-2.
24. Spaulding L, Trainer T, Janiec D. Prevalence of non-alcoholic steatohepatitis in morbidly obese subjects undergoing gastric bypass. Obes Surg 2003;13:347-9.
25. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006;45:600-6.
26. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 2005;129: 375-8.
27. Ratziu V, Bugianesi E, Dixon J, et al. Histological progression of non-alcoholic fatty-liver disease: a critical reassessment based on liver sampling variability. Aliment Pharmacol Ther 2007; 26: 821-30.
28. Friedman SL, Bansal MB. Reversal of hepatic fibrosis--fact or fantasy? Hepatology 2006;43(Suppl 1):S82-8.
29. Wells RG. Liver fibrosis: challenges of the new era. Gastroenterology 2009;136:387-8.
30. Sherlock S, Dick R, Van Leeuwen DJ. Liver biopsy today. The Royal Free Hospital experience. J Hepatol 1985;1:75-85.
31. Tobkes AI, Nord HJ. Liver biopsy: review of methodology and complications. Digestion 1995; 13: 267-74.
32. Maharaj B, Maharaj RJ, Leary WP, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 1: 523-5.
33. Schlichting P, Holund B, Poulsen H. Liver biopsy in chronic aggressive hepatitis. Diagnostic reproducibility in relation to size of specimen. Scand J Gastroenterol 1983; 18: 27-32.
34. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-8.
35. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57:1441-7
36. Le Calvez S, Thabut D, Messous D, et al. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. Hepatology 2004; 39: 862-3.
37. Lackner C, Struber G, Liegl B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005;41:1376-82.
38. Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004;3:8.
39. Poynard T, Morra R, Halfon P, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007;7: 40.
40. Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 6.
41. Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-3.
42. Nobili V, Alkhouri N, Alisi A, et al. Retinol-binding protein 4: A promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7:575-9.
43. Kanaka-Gantenbein C, Margeli A, Pervanidou P, et al. Retinolbinding protein 4 and lipocalin-2 in childhood and adolescent obesity: when children are not just "small adults". Clin Chem 2008;54:1176-82.
44. Lai M, Afdhal NH. Noninvasive markers of liver fibrosis. In: Howden CW, ed. Advances in Digestive Disease, Maryland, USA, AGA Institute Press, 2007; pp 121-33.
45. Christensen C, Bruden D, Livingston S, et al. Diagnostic accuracy of a fibrosis serum panel (FIBRO Spect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients. J Viral Hepat 2006;13:652-8.
46. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology (Baltimore) 2008;47: 455-60.
47. Sebastirani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006; 12: 3682-94.
48. Kawamoto M, Mizuguchi T, Katsuramaki T, et al. Assessment of liver fibrosis by a noninvasive method of transient elastography and biochemical markers. World J Gastroenterol 2006; 12: 4325-30.
49. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastrography (FibroScan): a prospective study. Gut 2006; 55: 403-8.
50. Yoneda M, Yoneda M, Mawatari H, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008; 40: 371-8.
51. Rockey DC. Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography. Gastroenterology 2008;134:8-14.
52. Talwalkar JA. Elastography for detecting hepatic fibrosis: options and considerations. Gastroenterology 2008;135:299-302.
53. Malik R, Afdhal N. Stiffness and impedance: the new liver biomarkers. Clin Gastroenterol Hepatol 2007;5:1144-6.
54. Huwart L, Sempoux C, Vicaut E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008;135:32-40.
55. Lim AK, Taylor-Robinson SD, Patel N, et al. Hepatic vein transit times using a microbubble agent can predict disease severity noninvasively in patients with hepatitis C. Gut 2005;54:128-33.
56. Das K, Chowdhury A. Hepatic fibrosis: can we treat it clinically? Trop Gastroenterol 2008;29:76-83.
57. Park GJ, Katelaris PH, Jones DB, et al. The C-caffeine breath test distinguishes significant fibrosis in chronic hepatitis B and reflects response to lamivudine therapy. Aliment Pharmacol Ther 2005;22:395-403.
58. Portincasa P, Grattagliano I, Lauterburg BH, Palmieri VO, Palasciano G, Stellaard F. Liver breath tests non-invasively predict higher stages of non-alcoholic steatohepatitis. Clin Sci (Lond) 2006;111:135-43.
59. Kaplan LM. Leptin, obesity, and liver disease. Gastroenterology 1998; 115:997-1001.
60. Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: A manifestation of lipotoxicity? Hepatology. 2002;36:403-9.